GLP-1 Receptor Agonists Beyond Weight Loss: What SELECT and FLOW Actually Tested

Semaglutide's benefits reach past weight loss. In the SELECT trial, it cut major cardiovascular events by roughly 20 percent in people with obesity and established heart disease but no diabetes, and in the FLOW trial it lowered major kidney events by about 24 percent in adults with type 2 diabetes and chronic kidney disease. Weight loss and glucose lowering explain only part of these results, which is exactly what makes the two dedicated outcome trials worth reading closely.

Why "beyond weight loss" is a real question, not marketing

GLP-1 receptor agonists were built to lower blood sugar. Weight loss came as a welcome side effect, and for a while the story stopped there. The harder scientific question is whether the heart and kidney protection seen with these drugs is simply the downstream reward of shedding weight and improving glucose, or whether the molecule does something more direct to blood vessels, the heart, and the kidney. That question matters because if the benefit were purely a weight effect, any equally effective weight-loss strategy should deliver the same organ protection. SELECT and FLOW were designed to test outcomes that a marketing claim cannot settle: hard events like heart attack, stroke, kidney failure, and death.

What SELECT actually tested

SELECT (published in the New England Journal of Medicine in 2023) enrolled people who were overweight or obese and had established cardiovascular disease but did not have diabetes. That design choice is the whole point. By excluding diabetes, the trial stripped out glucose lowering as an explanation, because these participants started with near-normal blood sugar and had little room to improve it.

Over a mean follow-up of more than three years, once-weekly semaglutide 2.4 mg reduced the primary composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by roughly 20 percent compared with placebo (a hazard ratio near 0.80). The absolute reduction was smaller, on the order of 1.5 percentage points, which is a useful reminder that a large relative number sits on top of a modest baseline event rate.

The mechanistic clue is in the timing. The event curves began to separate early, before most of the weight loss had accumulated. Prespecified analyses reinforced this: the size of a person's early weight loss did not cleanly predict who avoided cardiovascular events, and mediation modeling suggested that only about a third of the benefit could be statistically attributed to reductions in waist circumference. Put plainly, most of the cardiovascular protection in SELECT was not explained by how much weight came off. As commentary in the American Journal of Kidney Diseases appraising both trials noted, the effects point toward direct vascular and anti-inflammatory actions rather than weight alone. What SELECT could not do is isolate a single mechanism; it tells us the benefit is largely weight-independent, not precisely why.

What FLOW actually tested

FLOW (New England Journal of Medicine, 2024) asked a parallel question in the kidney. It randomized 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo, with a median follow-up of about 3.4 years. The primary endpoint was a composite of major kidney events: onset of kidney failure, a sustained 50 percent or greater fall in eGFR, or death from kidney or cardiovascular causes.

Semaglutide reduced that composite by about 24 percent (hazard ratio near 0.76), and the trial was stopped early for clear efficacy. Two secondary findings sharpen the picture. The rate of kidney function decline, measured as the annual eGFR slope, was meaningfully slower with semaglutide, by roughly 1.2 mL/min/1.73 m2 per year. And cardiovascular events fell by about 18 percent, with all-cause death reduced as well. A prespecified analysis showed the kidney benefit held whether or not participants were also taking an SGLT2 inhibitor, which suggests semaglutide adds protection on top of an already established kidney-protective drug class rather than merely overlapping with it.

Here again the weight-loss story is incomplete. FLOW used the 1.0 mg diabetes dose, which produces far less weight loss than the 2.4 mg obesity dose, yet the kidney signal was substantial. That pattern is hard to reconcile with a benefit driven mainly by weight, and points toward direct effects on kidney inflammation, blood pressure within the glomerulus, and albuminuria.

How much is weight loss, honestly

The fair reading is that weight loss contributes but does not account for the majority of the organ protection in either trial. SELECT's mediation work and early curve separation, and FLOW's strong effect at a lower-weight-loss dose, both push in the same direction. What neither trial establishes is a clean mechanistic ledger, and observational claims that these drugs protect every organ in every population go well beyond what was tested. SELECT studied people with prior cardiovascular disease and obesity without diabetes; FLOW studied type 2 diabetes with existing chronic kidney disease. Extending the numbers to healthier or very different groups is an assumption, not a finding.

This article is educational and is not medical advice. Whether any GLP-1 receptor agonist fits a given person depends on their full clinical picture, other conditions, tolerability, and cost, and that is a decision to be made with a treating clinician rather than inferred from a trial headline.

The bottom line

SELECT and FLOW moved GLP-1 receptor agonists from glucose-and-weight drugs to agents with demonstrated hard-outcome benefits for the heart and kidney in specific, well-defined populations. The evidence favors direct organ effects layered on top of, not replaced by, weight and glucose improvements. The honest caveats are the population limits, the modest absolute risk reductions behind the large relative ones, and the fact that "beyond weight loss" describes a direction the data support rather than a fully mapped mechanism.